Raymond James Upgrades Zymeworks, Says Encouraging Cancer Drug Is ‘Born to Run’

Raymond James Upgrades Zymeworks, Says Encouraging Cancer Drug Is 'Born to Run'Canadian biotech Zymeworks Inc . (NYSE: ZYME ) over the weekend announced more data from an ongoing clinical trial of a drug to treat HER2-type cancers and announced a Phase 2 trial in another cancer drug, …



Yahoo Finance

You may also like...